Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

3 Months Ended

Mar. 31, 2024

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

12. Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2024 and 2023 (in thousands, except share and per share amounts):


	Three Months Ended March 31,
	2024			2023
Net loss attributable to Adaptive Biotechnologies Corporation	$	(47,507	)	$	(57,699	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		145,787,527			143,511,142
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(0.33	)	$	(0.40	)

Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2024 and 2023, as they had an anti-dilutive effect:


	Three Months Ended March 31,
	2024		2023
Stock options outstanding		13,085,872		13,800,485
Nonvested restricted stock units outstanding		10,341,199		7,386,862
Maximum nonvested market-based restricted stock units outstanding eligible to be earned		2,547,757		904,006
Total		25,974,828		22,091,353